Lilly highlights retatrutide, Taltz and Zepbound data across rheumatologic diseases and obesity
Posted on November 6, 2026
Eli Lilly will present new Phase III and real-world data examining the relationship between obesity and rheumatologic conditions at the American College of Rheumatology Convergence 2026.
The company’s programme includes pivotal results for investigational retatrutide in adults with knee osteoarthritis and obesity or overweight, alongside one-year findings evaluating Taltz and Zepbound together in patients with psoriatic arthritis and obesity.
New Phase III results from the TRIUMPH-1 and TRIUMPH-4 studies showed that retatrutide produced substantial reductions in knee pain as well as body weight in adults with knee osteoarthritis pain and obesity or overweight.
Lilly said some participants reported no knee pain by the end of the studies.
The ACR presentations will provide further details on changes in pain, physical function and body weight.
Retatrutide is an investigational once-weekly therapy designed to activate the GIP, GLP-1 and glucagon receptors.
The company is studying whether the substantial weight reduction associated with the treatment can also improve symptoms and physical functioning in conditions where excess weight contributes to disease burden.
Approximately 80% of people with knee osteoarthritis are estimated to have obesity or overweight, which can be associated with greater pain and poorer functional outcomes.
Lilly will also present detailed one-year findings from the Phase IIIb TOGETHER-PsA study.
The trial evaluated Taltz, also known as ixekizumab, together with Zepbound, or tirzepatide, compared with Taltz alone in adults with psoriatic arthritis and obesity or overweight with at least one weight-related comorbidity.
The combination produced positive findings across measures of psoriatic arthritis disease activity, patient-reported outcomes and metabolic health at one year.
The programme is intended to assess whether simultaneously treating inflammatory disease and obesity can improve outcomes beyond targeting psoriatic arthritis alone.
Lilly said around 65% of people with psoriatic arthritis in the U.S. have obesity or overweight together with at least one weight-related comorbidity.
Excess weight is also associated with poorer treatment outcomes in psoriatic arthritis.
Adrienne Brown, Executive Vice President and President of Lilly Immunology, said the research is intended to explore the connection between rheumatologic conditions and obesity rather than treating the two disease burdens separately.
Additional ACR presentations will include clinical outcomes, modelling analyses and real-world evidence related to Taltz and Zepbound.
The data will be presented at ACR Convergence 2026, taking place from November 6 to 11 in Orlando.
Related Topics and Keywords
ACR Convergence 2026, Biopharma, clinical trials, Eli Lilly, GIP, GLP-1, glucagon, immunometabolic health, ixekizumab, knee osteoarthritis, knee pain, obesity, osteoarthritis, overweight, pharma news, phase III, Phase IIIb, physical function, psoriatic arthritis, retatrutide, rheumatology, Taltz, tirzepatide, TOGETHER-PsA, TRIUMPH-1, TRIUMPH-4, Zepbound™
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
